



Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Correction to: *Nature Communications*
<https://doi.org/10.1038/s41467-022-29000-5>,
published online 24 March 2022

<https://doi.org/10.1038/s41467-022-34545-6>

Published online: 17 November 2022



Peitao Zhang, Haixia Guan , Shukai Yuan, Huili Cheng, Jian Zheng, Zhenlei Zhang, Yifan Liu, Yang Yu, Zhaowei Meng, Xiangqian Zheng & Li Zhao

The original version of this Article contained an error in the author affiliations.

Affiliation 3 incorrectly read ‘Department of Endocrinology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, Guangdong Province, China.’

This has now been corrected in both the PDF and HTML versions of the Article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022